Executive Summary
Clinical trials have traditionally relied on scheduled visits, laboratory assessments, imaging, questionnaires, and other predefined measurements to evaluate treatment effects.
Digital technologies are expanding how these outcomes can be measured.
Digital endpoints are clinical trial measures derived from data collected through digital technologies such as wearable devices, smartphones, connected medical devices, sensors, and other digital tools. They can capture aspects of patient health continuously or in real-world settings rather than only during scheduled clinical visits.
This creates opportunities to measure changes that conventional trial assessments may miss.
Digital endpoints can provide information about physical activity, sleep, mobility, heart rate, respiratory patterns, cognitive performance, medication use, and other aspects of health, depending on the technology and therapeutic area.
For pharmaceutical companies, the opportunity is significant. Digital endpoints could make clinical trials more patient-centric, generate richer longitudinal data, and provide new ways to evaluate treatment effects.However, their value depends on scientific validity, reliable data collection, patient usability, analytical rigor, and regulatory acceptance.
What Exactly Are Digital Endpoints?
A digital endpoint is a clinical trial endpoint measured or derived using digital technology.
The technology itself is not the endpoint.
For example, a wearable device may continuously record movement. Researchers can then use validated measures derived from that data to assess mobility or physical function.
Digital endpoints can therefore transform raw digital measurements into clinically meaningful evidence.
They can be:
- Patient-reported
- Sensor-derived
- Device-derived
- Algorithmically derived
- Continuously or intermittently measured
The defining characteristic is that digital technology enables the collection or derivation of the measurement used to evaluate a clinical outcome.
Why Are Digital Endpoints Gaining Attention?
Traditional clinical assessments provide important information, but they are often collected at specific points in time.
A patient may visit a trial site every few weeks while experiencing changes in symptoms or physical function between visits.
Digital technologies can capture information during those periods.
Continuous or frequent measurement can provide a more detailed view of how a condition changes over time and how a patient responds to treatment.
This is particularly relevant for conditions where symptoms fluctuate or where changes in everyday behavior provide meaningful information about disease progression.
How Do Wearables Support Digital Endpoints?
Wearable devices are among the most visible technologies supporting digital endpoints.
Smartwatches, activity trackers, patches, and specialized sensors can collect physiological or behavioral measurements.
Depending on the device and study, these may include:
- Physical activity
- Step count
- Gait and movement
- Heart rate
- Sleep patterns
- Respiratory measurements
- Tremor or motor activity
These measurements can help researchers evaluate treatment effects outside traditional clinical environments.
However, the presence of a measurement does not automatically make it a valid endpoint. Researchers must demonstrate that the digital measure is reliable, relevant, and meaningfully connected to the clinical outcome being studied.
Can Smartphones Become Clinical Trial Tools?
Smartphones can extend digital endpoint collection beyond specialized wearable devices.
Because smartphones are widely used, they can support frequent data collection with relatively little additional hardware.
Applications can collect information through surveys, questionnaires, movement measurements, voice assessments, cognitive tasks, or other validated digital assessments.
Smartphones can also support remote participation in clinical studies.
This can reduce dependence on certain in-person assessments and potentially make it easier to collect information from patients in their normal environments.
How Are Digital Biomarkers Related to Digital Endpoints?
Digital biomarkers and digital endpoints are closely related but are not interchangeable terms.
A digital biomarker is generally a measurable characteristic collected through digital technology that can provide information about biological, physiological, or behavioral processes.
A digital endpoint uses a measurement to evaluate an outcome relevant to a clinical trial.
A digital biomarker can therefore contribute to a digital endpoint, but the endpoint must ultimately demonstrate relevance to the clinical question.
This distinction is important when evaluating whether a new digital measure is suitable for drug development.
Which Therapeutic Areas Could Benefit?
Digital endpoints may be particularly valuable in diseases where functional, behavioral, or physiological changes occur outside the clinic.
Potential applications include:
- Neurological disorders
- Cardiovascular diseases
- Respiratory diseases
- Sleep disorders
- Rare diseases
- Musculoskeletal conditions
- Metabolic diseases
For example, continuous movement data could potentially provide information about mobility in neurological or musculoskeletal conditions.
The appropriate endpoint depends on the disease, mechanism of action, treatment, patient population, and clinical question.
Can Digital Endpoints Improve Patient Experience?
Digital endpoints can reduce the need for some assessments to occur exclusively at clinical sites.
Patients may be able to provide information from home while continuing their normal routines.
This can be particularly valuable for people who have mobility challenges, live far from research sites, or find frequent clinic visits burdensome.
However, digital participation can also create challenges.
Patients may struggle with device setup, charging, connectivity, application use, or adherence to measurement protocols.
A digital endpoint is therefore only useful if the technology is practical for the population being studied.
How Could Digital Endpoints Improve Clinical Trial Data?
One potential advantage is greater measurement frequency.
Instead of obtaining a small number of observations during scheduled visits, researchers may be able to collect repeated measurements over weeks or months.
This can provide more detailed longitudinal information.
Digital endpoints can also capture patients in real-world environments rather than exclusively under clinical observation.
This may help researchers understand how treatment affects everyday function.
The additional data, however, creates analytical challenges. More data does not automatically mean better evidence.
What Role Does AI Play in Digital Endpoints?
AI can help analyze the large datasets generated by digital technologies.
Machine learning can identify patterns within sensor data, detect changes over time, and derive measurements from complex signals.
For example, algorithms may analyze movement patterns, speech, physiological signals, or other digital information to generate clinically relevant measures.
AI can therefore expand what can be extracted from digital data.
But AI-derived endpoints require careful validation. Researchers need to understand how the algorithm works, how consistently it performs across populations, and whether its output has meaningful clinical relevance.
What Are the Biggest Challenges?
Digital endpoints face several challenges before they can become broadly useful in clinical development.
Key issues include:
- Validation of digital measurements
- Device accuracy and reliability
- Patient adherence
- Data quality and missing data
- Algorithm performance
- Interoperability
- Privacy and cybersecurity
- Regulatory acceptance
Standardization is another challenge.
Different devices or algorithms may produce measurements that are not directly comparable, making consistency across studies important.
Will Regulators Accept Digital Endpoints?
Regulatory acceptance depends on the quality of the evidence supporting a particular digital endpoint.
Sponsors need to demonstrate that the measurement is technically reliable and clinically meaningful for its intended use.
Regulators also need confidence in how data are collected, processed, analyzed, and interpreted.
This means pharmaceutical companies cannot simply select a commercially available device and assume its data will be acceptable as a trial endpoint.
Digital endpoint development needs to be incorporated into the scientific and regulatory strategy of the clinical development program.
How Should Pharma Companies Use Digital Endpoints?
Pharmaceutical companies should begin with the clinical question rather than the technology.
The objective should be to identify an outcome that matters and determine whether digital measurement can capture it better than existing approaches.
A strong development process includes:
- Defining the clinical concept of interest
- Selecting an appropriate digital measurement
- Validating the technology
- Testing usability in the target population
- Establishing data-quality controls
- Developing the statistical analysis strategy
- Engaging regulatory stakeholders appropriately
This approach reduces the risk of adopting technology simply because it is available.
What Will the Future of Digital Endpoints Look Like?
Digital endpoints are likely to become more sophisticated as sensors, connected devices, smartphones, and analytical technologies improve.
Future trials may combine multiple digital measurements to create richer representations of patient health and treatment response.
AI could further enable continuous analysis of these datasets and help identify meaningful changes that are difficult to capture through occasional assessments.
The broader shift is toward measuring patients more continuously and in environments that better reflect everyday life.
Digital endpoints will not replace conventional clinical endpoints in every study. Instead, they are likely to expand the range of measurable outcomes available to researchers.
Conclusion
Digital endpoints are changing how pharmaceutical companies can measure treatment effects in clinical trials.
By using wearables, smartphones, sensors, connected devices, and validated analytical methods, researchers can collect more frequent and potentially more representative information about patients.
The opportunity is particularly significant for diseases where mobility, behavior, physiology, or symptoms change over time.
However, successful adoption requires more than technology. Digital endpoints must be scientifically validated, clinically meaningful, reliable, usable, and acceptable to regulators.
For pharma leaders, the strategic opportunity is to view digital endpoints as part of evidence innovation rather than simply a technology initiative.
As clinical development becomes increasingly decentralized and data-driven, digital endpoints could become an important component of how future trials measure what matters to patients.
Digital Endpoints are precisely defined clinical trial outcomes measured using digital technologies such as wearable devices, smartphones, connected sensors, and other digital health technologies. Unlike some traditional assessments that take place during scheduled clinic visits, Digital Endpoints can collect information remotely and, in some cases, continuously.
The FDA defines a clinical trial endpoint as a precisely defined variable used to reflect an outcome of interest and address a specific research question. When digital technologies are used to generate the measurement, the resulting data can support digitally derived measures and, when appropriately defined and validated, Digital Endpoints.
How Digital Endpoints Work
Digital Endpoints typically begin with data collected through a digital health technology. For example, a wearable could measure physical activity, heart rate, movement, or sleep. A smartphone or connected device can also collect information outside the clinical site.
